Tbio FBXO11 F-box only protein 11

Protein Summary

Description

Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as DTL/CDT2, BCL6 and PRDM1/BLIMP1. The SCF(FBXO11) complex mediates ubiquitination and degradation of BCL6, thereby playing a role in the germinal center B-cells terminal differentiation toward memory B-cells and plasma cells. The SCF(FBXO11) complex also mediates ubiquitination and degradation of DTL, an important step for the regulation of TGF-beta signaling, cell migration and the timing of the cell-cycle progression and exit. Binds to and neddylates phosphorylated p53/TP53, inhibiting its transcriptional activity. SCF(FBXO11) does not seem to direct ubiquitination of p53/TP53. This gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. The F-box proteins constitute one of the four subunits of ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbxs class. It can function as an arginine methyltransferase that symmetrically dimethylates arginine residues, and it acts as an adaptor protein to mediate the neddylation of p53, which leads to the suppression of p53 function. This gene is known to be down-regulated in melanocytes from patients with vitiligo, a skin disorder that results in depigmentation. Polymorphisms in this gene are associated with chronic otitis media with effusion and recurrent otitis media (COME/ROM), a hearing loss disorder, and the knockout of the homologous mouse gene results in the deaf mouse mutant Jeff (Jf), a single gene model of otitis media. Alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jun 2010]

Uniprot Accession IDs

• Q86XK2
• A1L491
• Q52ZP1
• Q53EP7
• Q53RT5
• Q8IXG3
• Q96E90
• Q9H6V8
• Q9H9L1
• Q9NR14
• Q9UFK1
• Q9UHI1
• Q9UKC2

Gene Name

• FBXO11

Ensembl ID

• ENST00000402508
• ENSP00000385398
• ENSG00000138081
• ENST00000403359
• ENSP00000384823

Symbol

• FBX11
• PRMT9
• VIT1
• UBR6
• VIT1
• FBX11
• PRMT9
• IDDFBA
• UG063H01

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
protein domain	0.97
transcription factor	0.8
transcription factor perturbation	0.8
transcription factor binding site profile	0.79
histone modification site profile	0.75

Protein Classes

PANTHER Classes

Protein / Ligase / Ubiquitin-protein Ligase / F-box Only Protein 11

DTO Classes

Protein / Enzyme / Ligase / Ubiquitin-protein Ligase / F-box Only Protein 11

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 49.35   (req: < 5)

Gene RIFs: 36   (req: <= 3)

Antibodies: 317   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 49.35   (req: >= 5)

Gene RIFs: 36   (req: > 3)

Antibodies: 317   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 9

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0